Evommune (EVMN) news
Recent news
Perceptive Advisors exits drug, BLTE, EVMN, NMRA in 2Q: 13F
Perceptive Advisors LLC, a biotech-focused investment firm, disclosed its second-quarter 2026 portfolio changes in a recent 13F filing. The firm exited several positions, including drugmaker Belite Bio (BLTE), Evommune (EVMN), and Neumora Therapeutics (NMRA), as part of its strategic rebalancing…
AInvest Wire · Aug 14, 2026Evommune Inc: Clear Street cuts target price to $28 from $53
Clear Street has revised its target price for Evommune Inc (NASDAQ: EVOM) from $53 to $28, reflecting a significant downward adjustment in its valuation outlook for the biotechnology company. The firm cited evolving market conditions and recent company developments as key factors in the…
AInvest Wire · Jun 30, 2026Evommune Inc: RBC cuts target price to $30 from $50
RBC Capital has revised its price target for Evommune Inc (NYSE:EVMN), cutting it to $30 from $50, while maintaining an outperform rating. The updated target reflects a 29% upside from the current stock price of $24, as of June 29, 2026. The firm highlighted the company’s progress in inflammation…
AInvest Wire · Jun 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.